Sigilon Therapeutics to Present at Barclays Global Healthcare Conference
Sigilon Therapeutics, Inc. (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the Barclays Global Healthcare Conference on March 11, 2021, at 10:55 a.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sigilon Therapeutics, Inc. (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the Barclays Global Healthcare Conference on March 11, 2021, at 10:55 a.m. EST. The presentation will be virtual, and a live webcast can be accessed on the company's website. Sigilon focuses on developing functional cures for chronic diseases using its Shielded Living Therapeutics™ platform, offering engineered cell-based therapies for conditions like hemophilia and diabetes. These therapies utilize Afibromer™ biomaterials to protect against immune rejection.
Details
News Market Reaction – SGTX
The recorded move for SGTX in the trading session of this news was -19.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Barclays Global Healthcare Conference. The presentation will take place on Thursday, March 11 at 10:55 a.m. EST, in a virtual format.
A live webcast of the presentation will be accessible under “Events and Presentations” in the Investors & Media page of the Company’s website at www.sigilon.com. A replay of the webcast will be available following the event on the Sigilon website.
About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.